External validation of a percutaneous coronary intervention mortality prediction model in patients with acute coronary syndromes

被引:9
|
作者
Hubacek, J
Galbraith, PD
Gao, M
Humphries, K
Graham, MM
Knudtson, ML
Ghali, WA
机构
[1] Univ Calgary, Fac Med, Dept Med, Calgary, AB T2N 4N1, Canada
[2] APPROACH, Calgary, AB, Canada
[3] APPROACH, Edmonton, AB, Canada
[4] Univ Alberta, Dept Med, Edmonton, AB T6G 2M7, Canada
[5] British Columbia Cardiac Registries, Vancouver, BC, Canada
[6] Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada
基金
加拿大健康研究院;
关键词
D O I
10.1016/j.ahj.2005.04.032
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The recently published Michigan outcome prediction model (MM) for inhospital mortality was developed and validated on a series of consecutive patients undergoing percutaneous coronary intervention (PCI). Our purpose was to externally validate the performance of the MM in 2 separate cohorts of patients with acute coronary syndrome (ACS) undergoing PCI in Canada. Methods A validation of the MM and development of an extended MM were performed on data describing 10050 patients from the APPROACH prospective cohort study between January 1995 and December 2000. Performance of both models was assessed on an external data set of 3259 PCI cases from the British Columbia Cardiac Registries. Only patients with a diagnosis of ACS were included in the study. Results The original MM predicted death rates ranging from 0.1% to 60.6%, but lacked accuracy to predict inhospital mortality as severity increased. The extended MM predicted death rates more widely from 0.0% to a high of 91.0% with better accuracy to predict inhospital death in patients with ACS undergoing PCI. The areas under the receiver operating characteristic curve for the MM and the extended MM on the external validation data set were 0.93. and 0.95, respectively. Conclusion The MM predicts death after PCI in patients with ACS and identifies a clear gradient of risk. However, the enhanced MM developed specifically for the subset of patients with ACS demonstrated better prediction and cross-validated performance. These prediction rules can be useful for risk-adjustment analyses and for prognostication for individual patients.
引用
收藏
页码:308 / 315
页数:8
相关论文
共 50 条
  • [31] Residual Plaque Burden in Patients With Acute Coronary Syndromes After Successful Percutaneous Coronary Intervention
    McPherson, John A.
    Maehara, Akiko
    Weisz, Giora
    Mintz, Gary S.
    Cristea, Ecaterina
    Mehran, Roxana
    Foster, Michael
    Verheye, Stefan
    Rabbani, Leroy
    Xu, Ke
    Fahy, Martin
    Templin, Barry
    Zhang, Zhen
    Lansky, Alexandra J.
    de Bruyne, Bernard
    Serruys, Patrick W.
    Stone, Gregg W.
    JACC-CARDIOVASCULAR IMAGING, 2012, 5 (03) : S76 - S85
  • [32] EptifibatideA Review of its Use in Patients with Acute Coronary Syndromes and/or Undergoing Percutaneous Coronary Intervention
    Monique P. Curran
    Gillian M. Keating
    Drugs, 2005, 65 : 2009 - 2035
  • [33] Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia
    Mahaffey K.W.
    Current Cardiology Reports, 2001, 3 (5) : 362 - 370
  • [34] The Rise of Transradial Artery Access for Percutaneous Coronary Intervention in Patients with Acute Coronary Syndromes in Australia
    Ocsan, Ryan James
    Doost, Ata
    Marley, Paul
    Farshid, Ahmad
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2020, 2020
  • [35] Eptifibatide - A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention
    Goa, KL
    Noble, S
    DRUGS, 1999, 57 (03) : 439 - 462
  • [36] Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention
    Antman, Elliott M.
    Wiviott, Stephen D.
    Murphy, Sabina A.
    Voitk, Juri
    Hasin, Yonathan
    Widimsky, Petr
    Chandna, Harish
    Macias, William
    McCabe, Carolyn H.
    Braunwald, Eugene
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (21) : 2028 - 2033
  • [37] Effect of Timing of Staged Percutaneous Coronary Intervention on Clinical Outcomes in Patients With Acute Coronary Syndromes
    Otsuka, Tatsuhiko
    Baer, Sarah
    Losdat, Sylvain
    Kavaliauskaite, Raminta
    Ueki, Yasushi
    Zanchin, Christian
    Lanz, Jonas
    Praz, Fabien
    Haener, Jonas
    Siontis, George C. M.
    Zanchin, Thomas
    Stortecky, Stefan
    Pilgrim, Thomas
    Windecker, Stephan
    Raeber, Lorenz
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (23):
  • [38] OUTCOMES OF PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING CHRONIC TOTAL OCCLUSION PERCUTANEOUS CORONARY INTERVENTION
    Simsek, Bahadir
    Kostantinis, Spyridon
    Karacsonyi, Judit
    Alaswad, Khaldoon
    Jaffer, Farouc A.
    Doshi, Darshan
    Khatri, Jaikirshan J.
    Poommipanit, Paul
    Gorgulu, Sevket
    Aygul, Nazif
    Rafeh, Nidal Abi
    Krestianinov, Oleg
    Choi, James W.
    Uretsky, Barry F.
    Davies, Rhian E.
    Goktekin, Omer
    ElGuindy, Ahmed Mohamed
    Jefferson, Brian K.
    Patel, Mitul P.
    Rangan, Bavana V.
    Rempakos, Athanasios
    Allana, Salman S.
    Sandoval, Yader
    Burke, M. Nicholas
    Brilakis, Emmanouil S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 1080 - 1080
  • [39] EptifibatideA Review of its Use in Patients with Acute Coronary Syndromes and/or Undergoing Percutaneous Coronary Intervention
    Karen L. Goa
    Stuart Noble
    Drugs, 1999, 57 : 439 - 462
  • [40] Eptifibatide: A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention
    Curran, MP
    Keating, GM
    DRUGS, 2005, 65 (14) : 2009 - 2035